At Work With: Shannon Boyle

Shannon Boyle
Shannon Boyle
SVP, Human Resources, Publicis ­Healthcare Communications Group

What was your biggest break?
When I was 25 and working as an HRIS Analyst, my EVP of HR decided he wanted to start a college recruiting program for our company and asked me to create it. The program became the hallmark of the HR department and the envy of our competitors. And the results stood the test of time—today, many of those first recruits are senior leaders within the business.

What's the best part of your job?
It is an absolute privilege to be entrusted with the development of our current and future leaders. It is so exciting to watch them grow and to share in their successes.

What books are you ­reading?
I am reading Team of Rivals by Doris Kearns Goodwin and Jack Kennedy: Elusive Hero by Chris Matthews. Each is a fascinating biography as well as a lesson in leadership.
Where will you be in five years?
I will still be fulfilling my purpose of discovering and developing great leaders.
If you were to write a book, what would the title be?
Busting the Myths of Career Advancement—What Really Matters and Why
You must be a registered member of MMM to post a comment.

Next Article in Careers

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.